Updated NSCLC Guidelines Incorporate PD-L1 Testing and Molecular Assays

Wayne Kuznar | May 30, 2017
Gregory J. Riely, MD, PhD

Gregory J. Riely, MD, PhD

Updates to the National Comprehensive Cancer Network (NCCN) guidelines for the management of advanced non–small cell lung cancer (NSCLC) call for routine molecular analysis and testing for PD-L1 expression, preferably at diagnosis. According to version 5.2017 of the NCCN guidelines,1 multiplexed biomarker testing is critically important to the selection of appropriate firstline and subsequent lines of therapy.

Those were the views of experts who presented changes in treatment guidelines during the 2017 NCCN Annual Conference, held March 23 to 25 in Orlando, Florida. The conference featured more than 20 panel discussions on advances in oncology care including updates on guidelines for specific tumor types and roundtables on issues such as payer policies and health disparities.

In NSCLC, the changes go beyond upfront molecular analysis. “Over the last year-and-a-half, we’ve learned that you have to test biomarkers again during the [treatment] course, and the best example of that we have is in patients with EGFR-mutant lung cancer,” said Gregory J. Riely, MD, PhD, vice chair, Clinical Trial Office, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City.

Because all patients with EGFR-mutant advanced NSCLC develop acquired resistance to an EGFR tyrosine kinase inhibitor (TKI), another molecular analysis is recommended at the time of resistance.

Initial Evaluation: PD-L1 Testing and Molecular Analysis

The latest version of the guidelines recommends that PD-L1, in addition to molecular analysis, be employed as a biomarker to direct initial therapy, with ≥50% expression established as the threshold for a positive result. The PD-L1 test “decides whether a patient has enough of the marker to warrant initial immunotherapy,” Riely said.

PD-L1 testing is currently “all over the map,” he added. Immunohistochemistry assays using 28-8, 22c3, or E1L3N as antibodies to detect PD-L1 expression were generally concordant in their findings, but the assay using the SP142 antibody was an outlier that detected significantly less PD-L1 expression in tumor cells than the other 3 platforms.2

In addition, PD-L1 expression is likely stable, he said, so there is no clear benefit to a repeat biopsy for assessment of PD-L1 unless the prior sample has been exhausted. In the case of molecular analysis, Riely suggested that institutions should customize their approach. Many use a combination of immunohistochemistry, fluorescence in situ hybridization, and DNA sequencing to detect abnormalities in key genes.

Treatment Algorithm

Based on the results of PD-L1 testing and molecular analysis, the NCCN developed an algorithm for initial therapy for patients with stage IV NSCLC. Patients with EGFR, ALK, or ROS1 mutations or rearrangements at diagnosis, which collectively constitute about 25% of NSCLC, should receive targeted therapy as first-line treatment (Table 1).

 

Table 1. Biomarker-Driven Frontline Therapy for Metastatic NSCLC

 Biomarker-Driven Frontline Therapy for Metastatic NSCLC
Pembrolizumab (Keytruda) is recommended as a first-line choice for patients with NSCLC whose tumors are positive for PD-L1 while being negative or unknown for mutations or rearrangements in EGFR, ALK, and ROS1 (category 1 recommendation). This recommendation is based on the results of the KEYNOTE-024 trial, which proved pembrolizumab superior to a platinum doublet combination on the endpoint of median progression-free survival (PFS; 10.3 vs 6.0 months; P <.001) as first-line therapy in patients with NSCLC with PD-L1 expression ≥50%. (At press time, the guidelines had not been updated to reflect the May 10 approval of pembrolizumab in combination with pemetrexed and carboplatin for previously untreated patients, regardless of PD-L1 expression).

Notably, Riely said, 44% of patients in KEYNOTE-024 crossed over from the chemotherapy arm to pembrolizumab, and even with this high rate of crossover, median overall survival was significantly superior with pembrolizumab compared with chemotherapy (64 vs 44 months, P = .005).3

The guidelines were drawn up before the FDA expanded the approval for pembrolizumab in combination with pemetrexed plus carboplatin as a frontline treatment for patients with metastatic or advanced nonsquamous NSCLC regardless of PD-L1 expression levels.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Optimizing Treatment and Management of Soft Tissue Sarcoma in Community OncologyNov 30, 20171.5
Community Practice Connections™: 1st Annual European Congress on Immunotherapies in Cancer™Dec 13, 20171.5
Publication Bottom Border
Border Publication
x